Related Experiment Video
Updated: Jul 7, 2026
Detection of Abnormal Prion Protein by Immunohistochemistry
Published on: May 5, 2023
IMPY, a potential beta-amyloid imaging probe for detection of prion deposits in scrapie-infected mice
Pu-Jiao Song1, Serge Bernard, Pierre Sarradin
1INSERM, U619, F-37000 Tours, France.
Introduction:
A potential single-photon emission computed tomography imaging agent for labeling of A beta plaques of Alzheimer's disease, IMPY (2-(4'-dimethylaminophenyl)-6-iodo-imidazo[1,2-a]pyridine), would be effective in detection of prion amyloid deposits in transmissible spongiform encephalopathies (TSEs).
Methods:
In vitro autoradiographic studies were carried out with [125 I]IMPY on brain sections from scrapie-infected mice and age-matched controls. Competition study was performed to evaluate the prion deposit binding specificity with nonradioactive IMPY.
Results:
Binding of [125 I]IMPY was observed in infected brain sections, while on age-matched control brain sections, there was no or very low labeling. Prion deposit binding was confirmed by histoblots with prion protein-specific monoclonal antibody 2D6. In the presence of nonradioactive IMPY, the binding of [125 I]IMPY was significantly inhibited in all regions studied.
Conclusions:
These findings indicate that IMPY can detect the prion deposits in vitro in scrapie-infected mice. Labeled with 123 I, this ligand may be useful to quantitate prion deposit burdens in TSEs by in vivo imaging.
Insights
IMPY effectively detects prion deposits in scrapie-infected mouse brains in vitro. This imaging agent shows potential for quantifying prion diseases like transmissible spongiform encephalopathies (TSEs) in vivo.
Area of Science:
- Neuroscience
- Radiochemistry
- Molecular Imaging
Background:
- Alzheimer's disease imaging agent IMPY (2-(4'-dimethylaminophenyl)-6-iodo-imidazo[1,2-a]pyridine) investigated for prion detection.
- Transmissible spongiform encephalopathies (TSEs) are characterized by prion amyloid deposits.
Purpose of the Study:
- To evaluate the efficacy of IMPY as an imaging agent for prion deposits in vitro.
- To assess the specificity of IMPY binding to prion aggregates.
Main Methods:
- In vitro autoradiography using [125I]IMPY on brain sections from scrapie-infected and control mice.
- Competition binding studies with nonradioactive IMPY to confirm specificity.
Main Results:
- Significant binding of [125I]IMPY observed in infected brain sections, with minimal labeling in controls.
- Histoblots confirmed prion deposit binding using a prion protein-specific antibody.
- Nonradioactive IMPY significantly inhibited [125I]IMPY binding, demonstrating specificity.
Conclusions:
- IMPY successfully detects prion deposits in vitro in a scrapie mouse model.
- IMPY labeled with 123I holds potential for in vivo quantification of prion burdens in TSEs.
